Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > At Home Dialysis on the rise...

<< Previous

Bullboard Posts

Next >>

Post by mercedesmanon Feb 03, 2022 5:31pm

270 Views

Post# 34395110

At Home Dialysis on the rise...

https://www.managedhealthcareexecutive.com/view/at-home-dialysis-on-the-rise

Due to:

Covid
Quality of Life
Individualized Therapy
reduce hospitalizations

June 2021

Key quotes:

“Dialysis clinics are already reporting higher home dialysis growth rates as a result of the COVID-19 pandemic and telehealth utilization.”

Technological advancements will be necessary for the success of home dialysis,” she says. “For a paradigm shift to home dialysis, the industry will need technology to develop a machine that is fully integrated and improves the ease of use.”

Fresenius’ The NxStage home hemodialysis machine is the first and only portable hemodialysis system cleared for home use in the U.S., according to the company, and the only machine small enough to take on the road or even on a plane.

“While the machine itself has been transformative, the 37% growth in home hemodialysis treatments among our patients in 2020 is also attributed to the depth of patient and staff training and real-time support that surrounds the device,” says Turk of Fresenius. “We also recently expanded our long-standing collaboration with DaVita (another dialysis company) to help bring NxStage home hemodialysis to more patients than ever before.”

Many people involved in kidney disease care expect the use of home hemodialysis to continue to increase over the next five years.

“We believe every patient should be considered for home dialysis” comments Turk. “The best way to help grow adoption of home dialysis is to have more patients prepared to make this choice earlier in the process.”